CDK6 antibody [N1C3]
GTX103992
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman, Mouse, Rat
TargetCDK6
Overview
- SupplierGeneTex
- Product NameCDK6 antibody [N1C3]
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1.14 mg/ml
- ConjugateUnconjugated
- Gene ID1021
- Target nameCDK6
- Target descriptioncyclin dependent kinase 6
- Target synonymscell division protein kinase 6; cyclin-dependent kinase 6; MCPH12; PLSTIRE; serine/threonine-protein kinase PLSTIRE
- HostRabbit
- IsotypeIgG
- Protein IDQ00534
- Protein NameCyclin-dependent kinase 6
- Scientific DescriptionThe protein encoded by this gene is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of Saccharomyces cerevisiae cdc28, and Schizosaccharomyces pombe cdc2, and are known to be important regulators of cell cycle progression. This kinase is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression and G1/S transition. The activity of this kinase first appears in mid-G1 phase, which is controlled by the regulatory subunits including D-type cyclins and members of INK4 family of CDK inhibitors. This kinase, as well as CDK4, has been shown to phosphorylate, and thus regulate the activity of, tumor suppressor protein Rb. [provided by RefSeq]
- ReactivityHuman, Mouse, Rat
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Extracellular vesicles from neurons promote neural induction of stem cells through cyclin D1. Song L et al., 2021 Sep 6, J Cell BiolRead more
- The CDK6-c-Jun-Sp1-MMP-2 axis as a biomarker and therapeutic target for triple-negative breast cancer. Luo CW et al., 2020, Am J Cancer ResRead more
- The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death. Hsin IL et al., 2019 Dec 31, Cancers (Basel)Read more
- Flavopereirine induces cell cycle arrest and apoptosis via the AKT/p38 MAPK/ERK1/2 signaling pathway in human breast cancer cells. Yeh HT et al., 2019 Nov 15, Eur J PharmacolRead more
- A major role of TWEAK/Fn14 axis as a therapeutic target for post-angioplasty restenosis. Mendez-Barbero N et al., 2019 Aug, EBioMedicineRead more
- Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation. Fararjeh AS et al., 2019 Apr 12, Cancers (Basel)Read more
- Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Ko JL et al., 2018 Nov, Environ ToxicolRead more
- Aqueous extracts of Paeonia suffruticosa modulates mitochondrial proteostasis by reactive oxygen species-induced endoplasmic reticulum stress in pancreatic cancer cells. Liu YH et al., 2018 Jul 15, PhytomedicineRead more
- Licochalcone A attenuates glioma cell growth in vitro and in vivo through cell cycle arrest. Lu WJ et al., 2018 Aug 15, Food FunctRead more
- Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer. Zhang X et al., 2017 Jan 23, J Hematol OncolRead more